Agenus' Updated Data Confirms Long-Term Potential Value

Jan. 24, 2023 9:51 AM ETAgenus Inc. (AGEN)13 Comments
William Meyers profile picture
William Meyers


  • Agenus reported updated Phase 1b colorectal cancer data at ASCO GI.
  • Botensilimab appears to offer a significant improvement over earlier CTLA-4 agents.
  • Phase 2 trials of botensilimab are underway in colorectal cancer, melanoma, and pancreatic cancer.

CTLA4 or CTLA-4 (3d structure), a protein receptor that, functioning as an immune checkpoint, downregulates immune responses.

ibreakstock/iStock via Getty Images

Agenus (NASDAQ:AGEN) reported a significant data update at ASCO-GI (American Society of Clinical Oncology Gastrointestinal Cancers Symposium) on Saturday, January 21, 2023. While data from the recently started Phase 2 trial, and from the planned Phase 3 trial, must be positive to

Data by YCharts

This article was written by

William Meyers profile picture
I provided stock and bond research and analysis to a small cap specialist investor, Lloyd Miller, from 2002 until his death in January 2018. For my own account I invest mainly in technology and biotechnology stocks. My technology and investment web site is, where readers can view the notes I take to make decisions and to write articles for Seeking Alpha.

Disclosure: I/we have a beneficial long position in the shares of AGEN, BMY, INCY, GILD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (13)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.